ACSL4 and metabolic dysfunction-associated steatotic liver disease: Previous studies have demonstrated the efficacy of abemaciclib in attenuating liver injury and liver fibrosis in a mouse model of nonalcoholic fatty liver disease by selectively inhibiting ACSL4 expression [21].